To Read The Complete Report With TOC Kindly Visit: http://www.researchmoz.us/epicast-report-nonalcoholic-steatohepatitis-epidemiology-forecast-to-2022-report.html
Nonalcoholic steatohepatitis (NASH) is
a common, often clinically silent liver disease characterized by the
presence of a fatty, inflamed, and damaged liver. It resembles alcoholic
liver disease, but occurs in people who drink little or no alcohol.
NASH is becoming increasingly common with the alarming epidemic of
obesity. As obesity is a major risk factor for other metabolic syndrome
diseases, such as type 2 diabetes and dyslipidemia, the incorporation of
weights from the ageand sex-specific prevalence of obesity in each of
the 6MM adds granularity to the forecast analysis, which allowed
GlobalData epidemiologists to provide a comprehensive forecast of the
prevalent cases of NASH in the 6MM.
Epidemiological analysis
forecasts that prevalent cases of NASH in the 6MM (US, France, Germany,
Italy, Spain, and UK) will grow by 8.24% over the next decade, from
29.38 million prevalent cases in 2012 to 31.80 million prevalent cases
in 2022. The US and Germany will continue to have the highest number of
prevalent cases in the 6MM during 20122022. The US will have 48.29%
(15.36 million cases) of all prevalent cases in the 6MM in 2022, with
the second largest annual growth rate (AGR) of 1.03% throughout the
forecast period. Changes in the definition of nonalcoholic, which is the
basis for defining NASH cases, the development of less invasive
gold-standard diagnostic methods for NASH, and changes in the prevalence
of the metabolic syndrome will influence the prevalence of NAFLD and
NASH during the forecast period.
View All Related Reports At : http://www.researchmoz.us/healthcare-market-reports-56.html
Scope
- The Nonalcoholic Steatohepatitis (NASH) EpiCast Report provides an overview of the risk factors and global trends of NASH in the 6MM (US, France, Germany, Italy, Spain, and UK). It includes a 10-year epidemiology forecast of NASH prevalent cases segmented by age (in five-year increments beginning at age 20 and ending at age =85 years) and sex in the 6MM.
- The NASH epidemiology report is written and developed by Mastersand PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 9MM.
Reasons to buy
- Develop business strategies by understanding the trends shaping and driving the global NASH market.
- Quantify patient populations in the global NASH market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for NASH therapeutics in each of the markets covered.
M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
http://www.researchmoz.us/
www.linkedin.com/company/researchmoz
https://twitter.com/researchmoz
https://www.facebook.com/pages/ResearchMoz/267379433319976
Blog: http://researchmoz.blogspot.com
No comments:
Post a Comment